Content Navigation
( All
None )
Target General Information |
Top |
Target ID |
T13017 |
Target Info
|
Target Name |
Syndecan-1 (SDC1) |
Synonyms |
SYND1; SDC; CD138 |
Target Type |
Clinical trial Target |
Gene Name |
SDC1 |
Biochemical Class |
Peptide translocating syndecan |
UniProt ID |
|
Targeted Antigens of CAR-T Cell Therapy |
Top |
CAR T-Cell Therapy Drug(s) |
CART-138 cells |
Drug Info
|
Phase 1/2 |
Multiple myeloma |
[1] |
CART-138 cells |
Drug Info
|
Phase 1/2 |
Multiple myeloma |
[2] |
CD138 CAR T cells |
Drug Info
|
Phase 1/2 |
Multiple myeloma |
[3] |
CAR138 T Cells |
Drug Info
|
Phase 1 |
Multiple myeloma |
[4] |
CAR-T cells targeting CD138 |
Drug Info
|
Clinical trial |
Multiple myeloma |
[5] |
References |
Top |
REF 1 |
ClinicalTrials.gov (NCT01886976) Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
|
REF 2 |
ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma
|
REF 3 |
ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
|
REF 4 |
ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
|
REF 5 |
ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.